Paper suggests Aravive compound could block Zika

In a study published Tuesday in Cell Reports, researchers from INSERM and Aravive Biologics Inc. (Houston, Texas) said Aravive’s preclinical candidate Aravive-S6 could

Read the full 230 word article

User Sign In